Ioversol Injection
» Ioversol Injection is a sterile solution of Ioversol in Water for Injection. It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amounts of ioversol (C18H24I3N3O9) and iodine (I). It may contain small amounts of suitable buffers and Edetate Calcium Disodium as a stabilizer. Ioversol Injection intended for intravascular use contains no antimicrobial agents.
Packaging and storage— Preserve in single-dose containers, preferably of Type I glass, protected from light.
Labeling— Label containers of Injection intended for intravascular injection to direct the user to discard any unused portion remaining in the container.
Identification—
A: The IR absorption spectrum of the test specimen, a zinc sulfide cell having a thickness of 0.01 to 0.02 mm being used, exhibits maxima only at the same wavelength as that of a similar preparation of USP Ioversol RS.
B: Heat about 1 mL in a crucible: violet vapors are evolved.
Bacterial endotoxins 85 It contains not more than 1.4 USP Endotoxin Units per mL of Injection.
pH 791: between 6.0 and 7.4.
Heavy metals, Method I 231
Standard solution— Into a 50-mL color-comparison tube pipet 2 mL of Standard Lead Solution (20 µg of Pb), and dilute with water to 5 mL.
Test solution— Into a 50-mL color-comparison tube, pipet a volume of Injection, equivalent to 1 g of ioversol, and dilute with water to 5 mL.
Procedure— For each of the tubes containing the Standard solution and the Test solution, adjust with 1 N acetic acid or 6 N ammonium hydroxide to a pH between 3.0 and 4.0, using short-range pH indicator paper as external indicator. Add 5.0 mL of ferrous sulfate solution (1 in 1000), dilute with water to 40 mL, and mix. Add 1.2 mL of thioacetamide-glycerin base TS and 2 mL of pH 3.5 Acetate Buffer, allow to stand for 5 minutes, and view downward over a white surface: the color of the solution from the Test solution is not darker than that of the solution from the Standard solution, treated in the same manner. The limit is 20 µg per g.
Other requirements— It meets the requirements under Injections 1.
Related compounds—
Mobile phase and Chromatographic system—Proceed as directed in the test for Related compounds under Ioversol.
Standard solution— Dissolve accurately weighed quantities of USP Ioversol Related Compound A RS and USP Ioversol Related Compound B RS in water to obtain a solution having known concentrations of 1.5 and 15 µg per mL, respectively.
Test solution— Dilute an accurately measured volume of Injection with water to obtain a solution containing 1 mg of ioversol per mL.
Procedure— Separately inject equal volumes (about 50 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each ioversol related compound in the volume of Injection taken by the formula:
100(CS / CU)(rU / rS)
in which CS is the concentration, in mg per mL, of USP Ioversol Related Compound A RS or USP Ioversol Related Compound B RS in the Standard solution; CU is the concentration, in mg per mL, of Ioversol in the Assay preparation; rU is the peak response obtained from the Test solution; and rS is the average peak response obtained from the Standard solution. Not more than 0.15% of ioversol related compound A and not more than 1.5% of ioversol related compound B are found.
Assay— Transfer an accurately measured volume of Injection, equivalent to about 0.5 g of ioversol, to a glass-stoppered, 125-mL conical flask, add 12 mL of 5 N sodium hydroxide, 20 mL of water, and 1 g of powdered zinc, connect the flask to a reflux condenser, and reflux for 30 minutes. Cool the flask to room temperature, rinse the condenser with 20 mL of water, disconnect the flask from the condenser, and filter the mixture. Rinse the flask and filter thoroughly, adding the rinsings to the filtrate. Add 40 mL of 2 N sulfuric acid, and titrate immediately with 0.05 N silver nitrate VS, determining the endpoint potentiometrically, using a silver-silver chloride double junction reference electrode and a silver billet electrode. Each mL of 0.05 N silver nitrate is equivalent to 13.45 mg of C18H24I3N3O9.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals
1-301-816-8178
(RMI05) Radiopharmaceuticals and Medical Imaging Agents 05
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
85 Radhakrishna S Tirumalai, Ph.D.
Senior Scientist
1-301-816-8339
(MSA05) Microbiology and Sterility Assurance
USP32–NF27 Page 2678